Arcutis Biotherapeutics, Inc.(ARQT)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Arcutis Biotherapeutics, Inc. (ARQT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ARQT at 62.9/100 on a 32-signal composite quality model, placing it at rank #675 of 2,962 stocks — the top 25% of the AI-ranked universe. ARQT scores in the top quartile across revenue growth (96.6), balance sheet strength (76.5). Areas of concern include institutional flow (21.1) and revenue scale (36.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 15.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Arcutis Biotherapeutics, Inc. reports quarterly revenue of $129.9M, net income of $15.0M, free cash flow of $12.5M. Top institutional holders of ARQT by reported 13-F value include SUVRETTA CAPITAL MANAGEMENT, BlackRock, Frazier Life Sciences Management, L.P., based on the most recent SEC filings. ARQT trades on the Nasdaq exchange and files with the SEC under CIK 1787306. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ARQT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Arcutis Biotherapeutics, Inc. directly from SEC EDGAR.